FDA accepts PTC Therapeutics’ NDA for Sepiapterin, aiming for breakthrough in PKU treatment

PTC Therapeutics, Inc. has announced a significant step forward in its mission to combat phenylketonuria (PKU) by receiving FDA acceptance for the New Drug Application ... Read More